Parkside Financial Bank & Trust’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$80.6K Hold
136
0.01% 774
2025
Q4
$66.3K Buy
136
+17
+14% +$7.92K 0.01% 855
2025
Q3
$49.9K Buy
119
+12
+11% +$4.04K ﹤0.01% 938
2025
Q2
$30.7K Buy
107
+4
+4% +$1.2K ﹤0.01% 1069
2025
Q1
$31.8K Buy
103
+33
+47% +$11.3K ﹤0.01% 976
2024
Q4
$24.7K Buy
70
+3
+4% +$1.1K ﹤0.01% 1022
2024
Q3
$24K Buy
67
+1
+2% +$338 ﹤0.01% 1013
2024
Q2
$21K Hold
66
﹤0.01% 1016
2024
Q1
$15.2K Buy
66
+23
+53% +$5.19K ﹤0.01% 1076
2023
Q4
$9.46K Sell
43
-20
-32% -$4.61K ﹤0.01% 1155
2023
Q3
$14.2K Hold
63
﹤0.01% 1014
2023
Q2
$13.9K Sell
63
-6
-9% -$1.33K ﹤0.01% 1012
2023
Q1
$15.5K Sell
69
-130
-65% -$32K ﹤0.01% 962
2022
Q4
$55.3K Buy
199
+96
+93% +$24.2K 0.02% 536
2022
Q3
$22K Hold
103
0.01% 783
2022
Q2
$24K Buy
+103
New +$20.9K 0.01% 761
2015
Q4
Sell
-45
Closed -$6K 1127
2015
Q3
$6K Buy
+45
New +$7.22K ﹤0.01% 760

Other funds holding UTHR

Parkside Financial Bank & Trust's UTHR Position: Q1 2026 in Review

Parkside Financial Bank & Trust held its United Therapeutics (UTHR) position steady in Q1 2026 at 136 shares worth $80.6K. The position accounts for 0.01% of the portfolio, ranked #774.

Parkside Financial Bank & Trust first reported a position in UTHR in Q3 2015 and has held it in 17 quarters since. 853 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Parkside Financial Bank & Trust held 136 shares of United Therapeutics worth $80.6K as of Q1 2026.
  • Parkside Financial Bank & Trust left its United Therapeutics share count unchanged in Q1 2026.
  • United Therapeutics made up 0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #774 holding.
  • Parkside Financial Bank & Trust first reported a position in United Therapeutics in Q3 2015 and has held it in 17 quarters since.
  • 853 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.